- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: Trump Also Calls for Medicare to Negotiate Drug Prices
What we're reading, January 27, 2016: Donald Trump joins Hillary Clinton and Bernie Sanders in calling for Medicare being given the ability to negotiate drug prices; $70 million approved for new patient-centered research projects; and the Zika virus likely to spread to the United States.
Hillary Clinton and Bernie Sanders aren’t the only vocal presidential hopefuls calling for Medicare to be able to negotiate with drugmakers—so is Donald Trump. The Republican frontrunner told the crowd that had come out to see him in New Hampshire that the nation could save $300 billion through such negotiations. Reuters reported that despite Trump’s comments, it seems unlikely that other Republicans will adopt such a proposal.
Until now, the mosquito-borne Zika virus, which has become a major health concern for newborns, has been mostly contained to South America and the Caribbean. However, the CDC has issued guidelines for evaluating and testing infants in the US suspected of being infected and now the World Health Organization stated it expects the Zika virus to spread to all of the Americas, reported The Washington Post. The virus may be the cause for thousands of infants born with brain damage.
In a news release, the Patient-Centered Outcomes Research Institute (PCORI) announced that it approved $70 million for 9 new patient-centered research projects. The newly approved projects include a study on the effectiveness of 2 medications commonly used to treat chronic obstructive pulmonary disease and the effectiveness of different approaches to help adults with serious mental illness quite smoking. To date, PCORI has approved or awarded more than $1.2 billion in research funding.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More
